PatchSiren cyber security CVE debrief
CVE-2026-78404 IBM CVE debrief
IBM Db2 is vulnerable to local privilege escalation via the db2pd utility. Affected versions include 11.5.0 through 11.5.9 and 12.1.0 through 12.1.5. This vulnerability could allow for local privilege escalation, which could have significant impacts in certain environments. Defenders and administrators should assess exposure and prioritize patching or mitigation. The CVE record and source item provide details on the vulnerability, including affected versions and a reference to a vendor advisory.
- Vendor
- IBM
- Product
- Db2
- CVSS
- MEDIUM 6.5
- CISA KEV
- Not listed in stored evidence
- Original CVE published
- 2026-10-12
- Original CVE updated
- 2026-10-13
- Advisory published
- 2026-10-12
- Advisory updated
- 2026-10-13
Who should care
Defenders and administrators responsible for IBM Db2 installations, especially in environments where local privilege escalation could have significant impacts, should assess exposure and prioritize patching or mitigation.
Why it matters
This vulnerability in IBM Db2 could allow for local privilege escalation, which could have significant impacts in certain environments. Defenders and administrators should assess exposure and prioritize patching or mitigation.
- Potential local privilege escalation
- Need for patching or mitigation to prevent exploitation
- Importance of monitoring systems for potential exploitation attempts
Technical summary
IBM Db2 11.5.0 through 11.5.9 and 12.1.0 through 12.1.5 are vulnerable to a local privilege escalation via the db2pd utility. This vulnerability has a CVSS score of 6.5 and a severity of MEDIUM. The vulnerability could allow for local privilege escalation, which could have significant impacts in certain environments. Defenders and administrators should assess exposure and prioritize patching or mitigation.
Defensive priority
Defenders should prioritize patching or mitigating this vulnerability, especially in environments where local privilege escalation could have significant impacts.
Recommended defensive actions
- Review and apply patches or updates for IBM Db2 versions 11.5.0 through 11.5.9 and 12.1.0 through 12.1.5
- Implement compensating controls to limit local privilege escalation
- Monitor systems for potential exploitation attempts
Evidence notes
The CVE record and source item provide details on the vulnerability, including affected versions and a reference to a vendor advisory. The vulnerability has a CVSS score of 6.5 and a severity of MEDIUM. Defenders and administrators should assess exposure and prioritize patching or mitigation. The db2pd utility is used for database administration and monitoring. Local privilege escalation could allow an attacker to gain elevated privileges and access sensitive data. The vendor advisory
Sources and references
Verified primary and authoritative sources
-
CVE-2026-78404 CVE Program record
Publisher, destination, and source semantics verified
URL: https://www.cve.org/CVERecord?id=CVE-2026-78404
CVE Program - Official CVE Program record with source-provided CVE metadata.
-
CVE-2026-78404 NVD vulnerability detail
Publisher, destination, and source semantics verified
URL: https://nvd.nist.gov/vuln/detail/CVE-2026-78404
NIST National Vulnerability Database - Official NIST NVD detail page and source-specific vulnerability assessment.
Supplemental references
-
IBM® Db2® is vulnerable to local privilege escalation via the db2pd utility
Unverified legacy reference
URL: https://raw.githubusercontent.com/CVEProject/cvelistV5/main/cves/2026/78xxx/CVE-2026-78404.json
cve_program_cvelist_v5
-
Source reference
Unverified legacy reference
URL: https://www.ibm.com/support/pages/node/7291612
Supplemental source - vendor-advisory, patch
Methodology and review provenance
AI-assisted synthesis based on stored public vulnerability evidence. System validation, approval state, and publication status do not by themselves establish human review of this revision. PatchSiren helps prioritize defensive review and does not prove exposure or remediation on any system.